Contemporary Management of HIV: Individualizing First-line ART

Download this expert-authored slideset to review national guidelines, key study data, and individual considerations for individualizing first-line ART regimens to treat HIV.
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 589 KB
Released: February 4, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Concise Clinical Care Options (CCO) presentation by Darrell H. S. Tan, MD, FRCPC, PhD, on approved and guideline-recommended oral HIV PrEP regimens

person default Darrell H. S. Tan, MD, FRCPC, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 29, 2021 Expired: July 28, 2022

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

REACH study: adherence to dapivirine vaginal ring and oral PrEP among African females 16-21 years, in Clinical Care Options (CCO) report from IAS 2021

Released: July 24, 2021

Dr Joseph Eron and Clinical Care Options (CCO): Weight gain in initial ART, GEMINI, ADVANCE trials, and more

Joseph J. Eron, Jr., MD Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue